Selected Start-Ups Founded in 2000 (03/00)
Executive Summary
{In Vivo} summarizes the technologies of several recently founded companies: Netherlands start-up [BioMaDe BV] will use nanotechnology to design and construct molecular devices for use in a variety of commercial applications. [DirectGene Inc.] is developing a tissue specific gene promoter technology for cancer gene therapy, based on the role of tumor-stromal interactions. [Esurg.com] will sell medical, surgical and pharmaceutical supplies and information to out-of-hospital healthcare providers. Founded in June 1999, [ImmunoGenec Biotechnologie GmbH] aims to develop, produce and market protein-based therapies for the immunotherapeutic treatment of certain cancers. [Quorex Pharmaceuticals Inc.] will discover anti-infectives using its discovery of a novel signaling pathway that occurs in wide variety of pathogenic bacteria. A joint venture of Rohm & Haas Co. and Argonex Inc, [RHeoGene LLC.] is developing enabling gene tools based on its proprietary Ecdyosyne Recepter-based gene switch system.
You may also be interested in...
QUOTED. 22 January 2021. Neil Moat.
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.
ICCR’s Growing Membership Ensures Diverse Cosmetics Regulatory Perspectives – PCPC
South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.
Woodcock Faces Maze Of Rules To Become Commissioner Nominee
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.
Need a specific report? 1000+ reports available
Buy Reports